A Phase II Study of Sorafenib Plus Tegafur/Uracil for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 14 May 2015
At a glance
- Drugs Sorafenib (Primary) ; Tegafur/uracil
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 14 Jul 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 14 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jul 2007 New trial record.